The central question surrounding ABX is whether the stock can reclaim momentum and push toward $15, a level cited by multiple analysts and one that would mark a decisive breakout above the company's 52-week high of $12.44. For a company that has spent much of the past year trading between $5 and the low teens, $15 represents a meaningful psychological milestone as well as a technical one.
Abacus Global Management, Inc. is a U.S.-listed stock — not an ETF — operating as an alternative asset manager specializing in life insurance policy monetization. The company, formerly known as Abacus Life, buys life insurance policies from consumers seeking liquidity and manages those policies over time, while also building out asset management, wealth management, and data-driven technology services through its LifeARC platform. Its segments include life solutions, asset management, and technology services.
The company recently reported second-quarter revenue of about $73 million, up roughly 30% year over year, driven by a 38% increase in its core life solutions business. Adjusted net income came in at approximately $27 million, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) near $40 million. For the full year, management reiterated adjusted net income guidance of $100 million to $106 million and adjusted earnings per share (EPS) of $1.00 to $1.05.
Several factors support a move toward $15. First, the company's origination engine is accelerating, with roughly $362 million in capital deployed in the first half of the year and strong inflows into its longevity funds. Second, a newly authorized $100 million share buyback, representing up to about 12% of outstanding shares, signals that management views the stock as undervalued. Third, the company's expanding technology fee revenue and its Manning & Napier distribution partnership offer potential pathways to more durable, higher-margin earnings.
The path to $15 is far from assured. Despite strong top-line growth, reported net income declined sharply in the most recent quarter, falling to roughly $6.6 million from about $17.6 million a year earlier, reflecting rising operating expenses tied to acquisitions and platform build-out. Major shareholders also sold shares over the past three months, which can weigh on sentiment. Most importantly, $15 is a level the stock has never sustained, meaning it would require not just operational execution but a genuine re-rating in valuation.
Analyst coverage is broadly constructive but divided. The consensus rating sits near "Moderate Buy," with average 12-month price targets clustering in the $12 to $14 range. Piper Sandler maintains a neutral stance, trimming its target from $13 to $12, while Texas Capital initiated coverage with a "strong buy" and a $15 target, and B. Riley has pointed toward $16. Maxim Group has also cited $15. In this context, the $15 level functions as the upper bound of mainstream analyst expectations rather than a consensus forecast.
From a technical analysis perspective, the $12.44 52-week high is the critical resistance level — a sustained close above it would confirm a breakout and open the door toward $15. On the downside, the $9 to $10 area, which aligns with the stock's 50-day moving average and its recent trading range, acts as near-term support. The $10 round number is also a widely watched psychological level for traders.
Investors tracking the market outlook for ABX can complement fundamental and technical research with tools such as Tickeron's AI Daily Buy/Sell Signals. This product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify changing market trends more efficiently.
Whether ABX can realistically reach $15 depends on a combination of execution and sentiment. The bullish case is credible: accelerating origination, a sizable buyback, and high-end analyst targets all point in that direction. Yet the obstacles are equally real, including margin pressure, inconsistent profitability, insider selling, and the fact that $15 would require the stock to trade above its all-time high. Investors monitoring the position should watch revenue quality, adjusted earnings trends, buyback activity, and whether the stock can first clear the $12.44 resistance level before entertaining the $15 scenario.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ABX has been loosely correlated with MET. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ABX jumps, then MET could also see price increases.
| Ticker / NAME | Correlation To ABX | 1D Price Change % |
|---|---|---|
| ABX | 100% | +5.46% |
| Life/Health Insurance industry (23 stocks) | 37% Loosely correlated | +0.42% |
| Insurance industry (117 stocks) | 29% Poorly correlated | +0.74% |
| mining industry (44 stocks) | 20% Poorly correlated | +2.35% |
| precious metals industry (31 stocks) | 20% Poorly correlated | +2.43% |
| gold industry (30 stocks) | 19% Poorly correlated | +2.41% |